Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-118 |
Sentence |
denotes |
Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. |
T2 |
119-325 |
Sentence |
denotes |
The multipotent drug suramin, which is currently being studied as an anticancer agent, was found to inhibit the interaction between the urokinase-type plasminogen activator (u-PA) and its cellular receptor. |
T3 |
326-485 |
Sentence |
denotes |
50% inhibition of binding was obtained with a suramin concentration between 30 and 60 micrograms/ml when using U937 cells and a ligand concentration of 0.3 nM. |
T4 |
486-582 |
Sentence |
denotes |
This concentration of the drug is well below the serum levels found in suramin-treated patients. |
T5 |
583-767 |
Sentence |
denotes |
Inhibition of binding was also demonstrated at the molecular level, using chemical cross-linking or an enzyme-linked immunosorbent assay-type technique based on the ligand interaction. |
T6 |
768-961 |
Sentence |
denotes |
The inhibition was not caused by a mere polyanion effect since polysulfates such as heparin, heparan sulfate, and pentosan polysulfate were non-inhibitory or showed only a very weak inhibition. |
T7 |
962-1086 |
Sentence |
denotes |
However, polysulfonated compounds with structures resembling suramin (i.e. trypan blue and Evans blue) did prove inhibitory. |
T8 |
1087-1220 |
Sentence |
denotes |
The inhibition found with suramin showed a concentration dependence consistent with a mixed competitive and noncompetitive mechanism. |
T9 |
1221-1281 |
Sentence |
denotes |
The off-rate of prebound ligand was accelerated by the drug. |
T10 |
1282-1490 |
Sentence |
denotes |
It is speculated that the present effect may contribute to the anti-invasive properties of suramin by destroying the cellular potential for localized plasminogen activation and proteolytic matrix degradation. |
T1 |
0-118 |
Sentence |
denotes |
Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. |
T2 |
119-325 |
Sentence |
denotes |
The multipotent drug suramin, which is currently being studied as an anticancer agent, was found to inhibit the interaction between the urokinase-type plasminogen activator (u-PA) and its cellular receptor. |
T3 |
326-485 |
Sentence |
denotes |
50% inhibition of binding was obtained with a suramin concentration between 30 and 60 micrograms/ml when using U937 cells and a ligand concentration of 0.3 nM. |
T4 |
486-582 |
Sentence |
denotes |
This concentration of the drug is well below the serum levels found in suramin-treated patients. |
T5 |
583-767 |
Sentence |
denotes |
Inhibition of binding was also demonstrated at the molecular level, using chemical cross-linking or an enzyme-linked immunosorbent assay-type technique based on the ligand interaction. |
T6 |
768-961 |
Sentence |
denotes |
The inhibition was not caused by a mere polyanion effect since polysulfates such as heparin, heparan sulfate, and pentosan polysulfate were non-inhibitory or showed only a very weak inhibition. |
T7 |
962-1086 |
Sentence |
denotes |
However, polysulfonated compounds with structures resembling suramin (i.e. trypan blue and Evans blue) did prove inhibitory. |
T8 |
1087-1220 |
Sentence |
denotes |
The inhibition found with suramin showed a concentration dependence consistent with a mixed competitive and noncompetitive mechanism. |
T9 |
1221-1281 |
Sentence |
denotes |
The off-rate of prebound ligand was accelerated by the drug. |
T10 |
1282-1490 |
Sentence |
denotes |
It is speculated that the present effect may contribute to the anti-invasive properties of suramin by destroying the cellular potential for localized plasminogen activation and proteolytic matrix degradation. |